These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23708664)

  • 1. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.
    Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW
    Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
    Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM
    Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in centrobin and Nek2 are associated with breast cancer susceptibility in a Chinese Han population.
    Wang H; Xie YT; Han JY; Ruan Y; Song AP; Zheng LY; Zhang WZ; Sajdik C; Li Y; Tian XX; Fang WG
    Breast Cancer Res Treat; 2012 Nov; 136(1):241-51. PubMed ID: 23001753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
    Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
    BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
    Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
    Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
    Marina M; Saavedra HI
    Front Biosci (Landmark Ed); 2014 Jan; 19(2):352-65. PubMed ID: 24389189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E2F activators signal and maintain centrosome amplification in breast cancer cells.
    Lee MY; Moreno CS; Saavedra HI
    Mol Cell Biol; 2014 Jul; 34(14):2581-99. PubMed ID: 24797070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nek2 kinase in chromosome instability and cancer.
    Hayward DG; Fry AM
    Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.
    Harrison Pitner MK; Saavedra HI
    PLoS One; 2013; 8(6):e65971. PubMed ID: 23776583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
    Lee J; Gollahon L
    Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nek2 protein kinase: a novel regulator of centrosome structure.
    Fry AM
    Oncogene; 2002 Sep; 21(40):6184-94. PubMed ID: 12214248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
    Li JJ; Li SA
    Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
    Zeng X; Shaikh FY; Harrison MK; Adon AM; Trimboli AJ; Carroll KA; Sharma N; Timmers C; Chodosh LA; Leone G; Saavedra HI
    Oncogene; 2010 Sep; 29(36):5103-12. PubMed ID: 20581865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis.
    Lee M; Oprea-Ilies G; Saavedra HI
    Oncotarget; 2015 Nov; 6(35):37316-34. PubMed ID: 26512919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators.
    Fry AM; Meraldi P; Nigg EA
    EMBO J; 1998 Jan; 17(2):470-81. PubMed ID: 9430639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of centrosome separation after DNA damage: a role for Nek2.
    Fletcher L; Cerniglia GJ; Nigg EA; Yend TJ; Muschel RJ
    Radiat Res; 2004 Aug; 162(2):128-35. PubMed ID: 15387139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
    Lee J; Gollahon L
    Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nek2 as a novel molecular target for the treatment of breast carcinoma.
    Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
    Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nek2A contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer.
    Wang S; Li W; Liu N; Zhang F; Liu H; Liu F; Liu J; Zhang T; Niu Y
    J Cell Biochem; 2012 Jun; 113(6):1904-14. PubMed ID: 22234886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.